RBC Capital maintains Astera Labs at Outperform, lowers price target to $400 from $500

What happened

RBC Capital kept its Outperform rating on Astera Labs but cut its price target to $400 from $500, a 20% reduction. The new target implies 71.2% upside from the November 3 closing price of $233.62. Recent analyst targets listed in the article ranged from $258 to $311.

Confirmed

Global impact / market context

The lower target signals RBC sees less potential value than before, even while retaining a positive rating. If investors respond by revising expectations, Astera Labs’ share price and its ability to raise funding through stock sales could be affected, though the article reports no market reaction.

Analyst inference

The four other recent analyst targets cited range from $258 to $311, below RBC’s revised $400 target. That spread shows analysts differ in their views, while the article provides no operating results, business outlook, or explanation for RBC’s reduction to assess the underlying causes.

Confirmed

What to watch

1. Check whether Astera Labs’ share price moves after the target cut; the article gives a November 3 closing price but reports no trading response to the announcement. Analyst inference
2. Compare subsequent analyst ratings and targets with RBC’s $400 figure and the cited $258–$311 range to see whether views converge or remain widely apart. Analyst inference
3. Look for company results or guidance that could explain analyst expectations; the supplied article gives no new information about revenue, costs, or business plans. Analyst inference

Evidence

• Original source link unavailable